摘要
目的评价复方甘草酸苷防治阿糖胞苷综合征的效果。方法收集2010年7月至2016年7月解放军第三〇三医院130例接受中大剂量阿糖胞苷治疗的血液系统恶性肿瘤患者，按随机数字表法将患者分为2组，每组65例。对照组给予阿糖胞苷化疗方案进行常规治疗，试验组在阿糖胞苷化疗方案的基础上联合应用复方甘草酸苷治疗。记录两组皮疹、发热的发生情况，监测血常规及肝、肾功能变化。结果试验组和对照组最终完成治疗纳入统计的患者分别为61、63例。试验组和对照组阿糖胞苷综合征发生率分别为8.2%（5/61）和41.3%（26/63），差异有统计学意义（χ2=18.1，P〈0.001）；皮疹发生率分别为1.6%（1/61）和12.7%（8/63），差异有统计学意义（χ2=16.3，P〈0.001）；发热的发生率分别为6.6%（4/61）和36.5%（23/63），差异有统计学意义（χ2=5.63，P=0.017）。两组的肝损伤发生率及最低血细胞计数比较，差异均无统计学意义（均P〉0.05）。结论复方甘草酸苷能有效减少阿糖胞苷综合征的发生，但需要更大规模的多中心研究加以确证。
ObjectiveTo evaluate the effect of compound glycyrrhizin on the prevention and cure of cytarabine syndromes.MethodsA total of 130 patients with hematological malignancies treated by moderate or high dose of cytarabine in the 303th Hospital of PLA from July 2010 to July 2016 were included. Patients were randomly divided into the control group and the experiment group by using random number table method, and each group had 65 patients. In the control group, patients were treated with cytarabine alone. In the experiment group, patients were treated with cytarabine plus compound glycyrrhizin. Skin rash and fever in patients of the two groups were also recorded. Results of blood routine tests, liver and kidney function tests were monitored during the treatment.
ResultsSixty-one patients in the experiment group and 63 patients in the control group were enrolled finally. In experiment group and control group, the differences in the incidence of cytarabine syndromes [8.2% （5/61） vs. 41.3% （26/63）, χ2= 18.1, P 〈 0.001], skin rash [1.6% （1/61） vs. 12.7% （8/63）, χ2= 16.3, P 〈 0.001], and fever [6.6% （4/61） vs. 36.5% （23/63）, χ2= 5.63, P 〈 0.017] were statistically significant. There was no significant difference of the incidence of liver injury and minimum blood cell count between the two groups （P 〉 0.05）.
ConclusionCompound glycyrrhizin can effectively reduce the incidence of cytarabine syndromes, but the larger size and multiple center studies are needed to further verify the effect.
作者
孔祥敬
梁菠
廖桂萍
冯琪荣
李瑶芸
尹晓林
周天红
Kong Xiangjing;Liang Bo;Liao Guiping;Feng Qirong;Li Yaoyun;Yin Xiaolin;Zhou Tianhong(Department of Hematology,the 303th Hospital of PLA,Nanning 530021,China)
出处
《白血病．淋巴瘤》
CAS
2018年第9期529-532,共4页
Journal of Leukemia & Lymphoma
基金
广西自然科学基金（2015GXNSFAA13916）
